News | February 17, 2009

PET, PET/CT Studies Inched Up Just 4 Percent in 2008

February 17, 2009 - The total PET and PET/CT patient studies increased only 4 percent, from 1,457,400 to 1,520,800, compared to estimates for 2007 provided by respondents to a 2008 survey by IMV Medical Information Division, representing a slowdown in procedure growth.
Despite the 2008 figures represent a 35 percent increase over the same survey by IMV done in 2005, which estimated 1,129,900 patient studies were performed using PET or PET/CT, the recent slowdown may be caused by the Deficit Reduction Act (DRA) of 2005, indicated Lorna Young, senior director, Market Research at IMV.
“The estimated 1,520,800 clinical PET patient studies performed in 2008 represent a 35% increase over IMV’s 2005 estimate of 1,129,900 patient studies, for an average annual growth rate of 10.4 percent over the three-year period,” said Young. “With the advent of the Deficit Reduction Act (DRA) of 2005, related legislation against self-referral for standalone imaging centers, the increased scrutiny of third party insurers in their preauthorization processes and the reduction in the availability of capital, the market for PET purchases may continue to slow over the next few years.”
The report just released by IMV accounted for PET studies performed in 2,000 U.S. hospital and non-hospital sites, using fixed or mobile PET/CT or PET scanners.
Young added, “The PET market for fixed PET imaging units is still relatively early in its adoption cycle, as over half of the PET sites use a mobile service provider, while over 900 sites own one or more fixed PET or PET/CT scanners. A market forecast scenario presented in the report shows that over the next few years, 55 percent of the PET scanner demand will come from first buyers, who currently use mobile services, 30 percent will be replacement buyers and 15 percent will be additional buyers.”
The survey also noted that of the patient studies performed on PET or PET/CT scanners, 94 percent are for oncology applications, and 6 percent are for cardiology and neurology applications.

For more information: www.mvinfo.com

Related Content

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
News | PET-CT | February 06, 2019
Technological advancements in positron emission tomography/computed tomography (PET/CT) offer both clinicians and pat
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...